Eli Lilly & Co (1LLY) Stock Price & Analysis
1LLY Stock Chart & Stats
- Day’s Range
- EUR 1,238.60 - EUR 1,267.80
- 52-Week Range
- EUR 727.60 - EUR 1,293.40
- Previous Close
- EUR 1,273.40
- Volume
- N/A
- Average Volume (3M)
- 537
- Market Cap
- EUR 1.19T
- Enterprise Value
- EUR 1.08T
- Total Cash (Recent Filing)
- EUR 4.88B
- Total Debt (Recent Filing)
- EUR 49.50B
- Price to Earnings (P/E)
- 45.7
- Beta
- 0.46
- Next Earnings
- Feb 10, 2027 (Est.)
- EPS Estimate
- 9.99
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- 0.46%
Bulls Say, Bears Say
Bulls Say
Exceptional Revenue Growth
Rapid growth across leading metabolic medicines and multiple therapeutic areas indicates strong demand, expanding patient adoption, and increasing commercial scale. Broadening growth beyond a single product can support durable revenue momentum and strengthen Lilly’s position over the next several quarters.
High Margins And Cash Generation
Very high profitability and substantial cash generation give Lilly meaningful capacity to fund research, manufacturing expansion, acquisitions, dividends, and debt obligations internally. Strong operating economics also provide resilience as the company invests behind continued product and pipeline growth.
Diversified Pipeline And Capacity Investment
Investment outside obesity reduces reliance on one therapeutic category and preserves multiple avenues for future growth in oncology, immunology, neuroscience, and other diseases. Major manufacturing additions should also support supply for expanding products and future launches.
Bears Say
Persistent Pricing Pressure
Lower realized prices can constrain revenue quality and margin expansion even when prescription volumes grow. Continued payer and government pricing pressure may require Lilly to depend increasingly on sustained volume gains, product launches, and mix improvements to preserve earnings momentum.
Meaningful Leverage
A debt-to-equity ratio around 1.23 leaves Lilly more exposed to funding costs and balance-sheet strain than an unlevered peer. Although equity has expanded, leverage can reduce financial flexibility during downturns or when the company is simultaneously funding major investments and acquisitions.
Uneven Free-cash-flow Consistency
Current cash generation is excellent, but historical volatility and weaker recent growth show that accounting earnings do not always translate consistently into deployable cash. Working-capital needs and investment spending could therefore moderate funding flexibility across future periods.
1LLY FAQ
What was Eli Lilly & Co’s price range in the past 12 months?
What is Eli Lilly & Co’s market cap?
When is Eli Lilly & Co’s upcoming earnings report date?
How were Eli Lilly & Co’s earnings last quarter?
Is Eli Lilly & Co overvalued?
Does Eli Lilly & Co pay dividends?
What is Eli Lilly & Co’s EPS estimate?
How many shares outstanding does Eli Lilly & Co have?
What happened to Eli Lilly & Co’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Eli Lilly & Co?
What is the TipRanks Smart Score and how is it calculated?
Eli Lilly & Co Stock Smart Score
Company Description
Eli Lilly & Co
Eli Lilly and Company is a prominent global pharmaceutical firm dedicated to the research, development, and commercialization of human medicines across the world. Its therapeutic offerings include a comprehensive suite of diabetes medications. This encompasses various insulin formulations like Basaglar, the Humalog family (e.g., Mix 75/25, U-100, U-200, Mix 50/50), insulin lispro products (including protamine and mix 75/25), and the Humulin line (e.g., 70/30, N, R, U-500). Furthermore, Eli Lilly provides specialized treatments for type 2 diabetes, such as Jardiance, Trajenta, and Trulicity. In oncology, Eli Lilly offers a robust portfolio targeting various cancers. These include Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza, indicated for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal and various head and neck cancers; Retevmo, used in metastatic NSCLC, medullary thyroid, and other thyroid cancers; Tyvyt for relapsed or refractory classic Hodgkin's lymphoma and non-squamous NSCLC; and Verzenio, prescribed for HR+, HER2- metastatic breast cancer, node-positive, and early breast cancer. For autoimmune and inflammatory conditions, the company markets Olumiant for rheumatoid arthritis, and Taltz, which addresses plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Addressing neurological and pain management needs, Eli Lilly provides Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain. Emgality is available for migraine prevention and episodic cluster headaches, while Zyprexa treats schizophrenia, bipolar I disorder, and aids in bipolar maintenance. Other significant products include Bamlanivimab and etesevimab, along with Bebtelovimab, both developed for COVID-19. Cialis is offered for erectile dysfunction and benign prostatic hyperplasia, and Forteo is available for osteoporosis. Eli Lilly actively engages in strategic collaborations with numerous partners, including Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Established in 1876, Eli Lilly and Company maintains its corporate headquarters in Indianapolis, Indiana.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- David A. Ricks
- Employees
- 50,000
- Website
- www.lilly.com
- Address
- Lilly Corporate Center, Indianapolis, IN, 46285, US
Eli Lilly & Co (1LLY) Earnings & Revenues
1LLY Company Deck
1LLY Earnings Call
Earnings Call SentimentPositive
The call was strongly positive. Lilly reported 39% quarterly revenue growth, raised full-year guidance, delivered broad product and international growth, demonstrated strong uptake for Mounjaro, Zepbound, the Medicare Bridge program, and Foundayo, and advanced regulatory, clinical, manufacturing, and business-development initiatives. The main challenges were U.S. and expected future pricing pressure, nonrecurring 2026 revenue benefits, higher investment spending, oral-adherence uncertainty, adverse-event discontinuations at the highest Olora-TZP dose, and ongoing regulatory and reimbursement timing. Highlights significantly outweighed the lowlights.
View all IT:1LLY earnings summaries1LLY Net sales Breakdown
- 35.23% Mounjaro
- 20.78% Zepbound
- 8.78% Verzenio
- 35.21% Other products
1LLY Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 14 | 2 | 6 |
| Technical Analysis | 2 | 2 | 6 |
| Moving Averages | 12 | 0 | 0 |
